The percentage of patients with TP53 mutation in our cohort is higher than previously reported in elderly AML patients [36–38], which could be easily explained by the high proportion of adverse cytogenetics and secondary AML in this group of patients deemed unfit for IC. This evidence concerns the gene TP53 and acute myeloid leukemia.